Revolutionizing AAV Gene Therapy Manufacturing with Viralgen’s Pro10™ Suspension Technology

A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

The Pro10™ cell line is a new technology that enhances the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology is designed to address the challenges associated with large-scale manufacturing in AAV gene therapies. The cells have been fully characterized and licensed for gene therapy development by various biopharmaceutical companies.

Viralgen utilizes the Pro10™ cells as the core of a reliable and scalable rAAV vector manufacturing process. These cells have been optimized for rAAV production and can be scaled up to 2000L, showcasing consistent and reproducible cell growth rates. They have demonstrated similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes.

The Pro10™ cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors, significantly contributing to the production of innovative gene therapies. For more information on this animal component-free suspension Pro10™ cell line, access the full PDF detailing its capabilities, which can help reduce process development time and costs.

Leave a Reply